Healthineers Revenue Outlook Cut
Siemens Healthineers Cuts 2026 Revenue Forecast Amid Diagnostics Weakness and China Policy
Anonymous
Siemens Healthineers slashed its 2026 revenue growth forecast on Friday, cutting the target from 5%–6% down to just 3.5%–4.0%, according to Reuters. The German medical technology company blamed weak performance in its diagnostics business, hit by China's procurement policies and lower reimbursement rates.
Third-quarter revenue came in at €5.76 billion ($6.63 billion), a rise of just 1.8%. That missed analyst estimates by 0.8%, according to Reuters. On a brighter note, the company raised its adjusted earnings per share outlook to €2.35–€2.45, partly thanks to U.S. tariff refunds.
China's Policies Drag Down Diagnostics Revenue
China is at the heart of the forecast cut. The country's procurement policies — which push hospitals to buy cheaper, often domestic equipment — are squeezing Siemens Healthineers' diagnostics sales, according to Reuters. Lower reimbursement rates, meaning hospitals get paid less per test, are making the problem worse.
Diagnostics is a core part of the company's business. It covers blood tests, lab equipment, and imaging tools used in hospitals worldwide. When China tightens the purse strings, it hits Siemens Healthineers hard. The company had already flagged pressure in this segment earlier in the year.
Revenue Growth Target Cut Nearly in Half
The new forecast of 3.5%–4.0% growth is a steep step down from the previous 5%–6% target. That is nearly half the original expectation. Market Screener noted the revision came alongside the company's third-quarter earnings release on Friday.
Q3 revenue of €5.76 billion missed the LSEG analyst consensus by 0.8%, according to Reuters. LSEG is a financial data firm that compiles expert forecasts. A miss of that size signals the business is growing slower than Wall Street — and Frankfurt — expected.
U.S. Tariff Refunds Boost Earnings Per Share Outlook
Not everything went the wrong way. Siemens Healthineers raised its adjusted earnings per share outlook to a range of €2.35 to €2.45. The company credited U.S. tariff refunds for the improvement, according to Reuters. Tariff refunds are money returned to companies that paid import taxes on goods moving between countries.
The higher earnings outlook gives investors some comfort even as revenue growth disappoints. It suggests the company is managing its costs well. Still, the revenue cut is the bigger headline — growth of 3.5% to 4.0% is a modest pace for a company of this size.
Broader Pressures Facing Medical Technology Firms in 2025
Siemens Healthineers is not alone in facing China-related headwinds. Many Western medical device and diagnostics companies have seen Beijing shift buying toward homegrown suppliers. This is part of a wider Chinese government push to reduce reliance on foreign technology in hospitals, according to Market Screener.
U.S. tariffs add another layer of complexity for global health tech firms. Companies that make products in one country and sell them in another face shifting costs. Siemens Healthineers managed to turn some of those tariff costs into refunds — a small win inside a tough quarter.
Sentiment
NeutralNEGATIVENEUTRALPOSITIVE
Publishers
5
Articles
3
Reach
5
A
AnonymousAuthor